Analysts See $-0.01 EPS for DiaMedica Therapeutics Inc. (DMA)

November 10, 2018 - By James Guidry

DiaMedica Therapeutics Inc. (CVE:DMA) Logo

Analysts expect DiaMedica Therapeutics Inc. (CVE:DMA) to report $-0.01 EPS on November, 26.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.01 EPS. After having $-0.03 EPS previously, DiaMedica Therapeutics Inc.’s analysts see -66.67 % EPS growth. The stock decreased 4.55% or $0.02 during the last trading session, reaching $0.42. About 96,316 shares traded. DiaMedica Therapeutics Inc. (CVE:DMA) has 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of novel recombinant proteins and monoclonal antibodies. The company has market cap of $65.85 million. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein with a focus on acute vascular diseases, such as acute ischemic stroke and kidney injury indications. It currently has negative earnings. It also develops DMDx, a companion diagnostic in vitro assay for kidney diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.